GLACEUM

History

  • 2022
      • Mar.
      • HSG4112 Phase 2a study first dosing (obesity)
  • 2021
      • Nov.
      • HSG4112 Phase 2a study IND effective (obesity)
      • Sep.
      • HSG4112 Phase 1 study completed
  • 2019
      • Dec.
      • HSG4112 Phase 1 MAD study initiated
      • July
      • HSG4112 Phase 1 SAD study completed
  • 2018
      • Sep.
      • HSG4112 Phase 1 SAD study initiated
      • Feb.
      • HSG4112 Phase 1 study IND effective
  • 2017
      • Aug.
      • HSG4112 Preclinical study completed (obesity)
      • Mar.
      • Certificated as Venture Business and Company-affiliated Research Institute
  • 2016
      • Apr.
      • Company renamed Glaceum
      • Jan.
      • HSG4112 Preclinical study initiated
  • 2014
      • Dec.
      • IP registered
      • Apr.
      • Spin off from Erum Biotechnologies Inc.
  • 2006~
    2013
    2006~2013.
      • Drug discovery